A61K 31/45
Having oxo groups directly attached to the heterocyclic ring
Official title: having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
A61K31/45 (Having oxo groups directly attached to the heterocyclic ring) appears on 265 US grants and 427 published applications in this corpus.
Search patents in A61K- Granted patents
- 265
- Published applications
- 427
- Assignees
- 243
- Inventors
- 968
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 2 | 0 |
| 1978 | 3 | 0 |
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 3 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 7 | 0 |
| 1999 | 1 | 0 |
| 2000 | 3 | 0 |
| 2001 | 1 | 1 |
| 2002 | 4 | 3 |
| 2003 | 4 | 8 |
| 2004 | 2 | 7 |
| 2005 | 3 | 7 |
| 2006 | 3 | 9 |
| 2007 | 2 | 9 |
| 2008 | 6 | 14 |
| 2009 | 2 | 8 |
| 2010 | 5 | 12 |
| 2011 | 7 | 21 |
| 2012 | 5 | 14 |
| 2013 | 5 | 12 |
| 2014 | 12 | 20 |
| 2015 | 16 | 36 |
| 2016 | 19 | 19 |
| 2017 | 9 | 23 |
| 2018 | 19 | 25 |
| 2019 | 20 | 32 |
| 2020 | 17 | 24 |
| 2021 | 19 | 20 |
| 2022 | 18 | 27 |
| 2023 | 8 | 21 |
| 2024 | 10 | 27 |
| 2025 | 11 | 18 |
| 2026 | 8 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- TEAD inhibitors29 Sep 2026US 12,747,207 B2Orion Corporation
- Bacterial DNA gyrase inhibitors and methods of use thereof25 Aug 2026US 12,714,692 B2The Florida International University Board of Trustees
- Combination therapy for the treatment of cancer21 Apr 2026US 12,605,372 B2Celgene Corporation
- C3-carbon linked glutarimide Degronimers for target protein degradation21 Apr 2026US 12,605,450 B2C4 Therapeutics, Inc.
- Treatment of Fabry disease in ERT-naïve and ERT-experienced patients14 Apr 2026US 12,599,594 B2Amicus Therapeutics, Inc.
- Testosterone and difluoromethylornithine combination therapy for prostate cancer24 Sep 2026US 2026/0284076 A1The Johns Hopkins University
- Use of retinoic acid receptor activator and composition thereof in regeneration and repair of mammals17 Sep 2026US 2026/0272871 A1Beijing Institute for Stem Cell and Regenerative Medicine
- Bioactive phytochemicals10 Sep 2026US 2026/0263440 A1Phytoquest Limited
- Heterocycloalkyl beta-hydroxy alkyl amines for use in the treatment of hyperglycaemia and disorders characterised by hyperglycaemia20 Aug 2026US 2026/0242335 A1Atrogi AB
- Combination therapy for the treatment of cancer30 Jul 2026US 2026/0216161 A1Celgene Corporation
Most cited
By later US patents
- Substituted 2-(2,6-dioxopiperidin-3-yl)- phthalimides and 1-oxoisoindolines and method of reducing TNFα levels133US 6,395,754 B1Celgene Corporation, et al. · 2002
- Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants85US 5,540,931 A1996
- Retinoid inhibition of expression of VEGF80US 6,001,885 ACentre International de Recherches Dermatologiques · 1999
- Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones68US 9,056,101 B2Amicus Therapeutics, Inc. · 2015
- Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin65US 6,455,518 B2Novartis AG · 2002